Fellowship Application Guidelines

Fellowships from NCC are established at $40,000 per annum for post-doctoral awards, and are awarded annually. Fellowships are intended for applicants under age 35 with less than two years of post- doctoral laboratory experience, except in extenuating circumstances. Fellowships are also limited to applicants having received no more than one prior fellowship or one career development award. Individuals receiving concurrent support from another organization are not eligible to apply.

Preference will be given to studies that have direct relevance to the diagnosis and treatment of human cancer.

Fellowship awards are not necessarily restricted to salary. Depending on the circumstances, part of the funds may be used for supplies or other valid expenses, which should be listed in the proposed budget. NCC reserves the right to delete any item it deems inappropriate.

The fellowship may be transferable upon application and review, in the event that the fellow leaves the sponsoring organization.

Fellowships generally are extended for a second year. However, adequate progress must have been demonstrated during the first year as evidenced through a progress report submitted with renewal application. Awards are limited to one per laboratory. There can be several different applications if they are on different topics. However, only one award could be made per lab in any round of applications.

NCC fellowship grants do not include funds for institutional overhead and a statement by the institution accepting this condition is required.


2019 New and Renewed Research Grants


2019 Grants


Total Grand Funding To Date

National Cancer Center 2019/2020 Grants

The following post-doc fellowship grants and renewals were approved for 2019/2020

Polina Vaitsenfeld, Ph.D.

The Rockefeller University, NY, NY

PROJECT: Enhancing antibody-mediated immunity against tumor-associated carbohydrate antigens

Darko Barisic, Ph.D.

Weill Medical College of Cornell Univ

PROJECT: Role of chromatin remodeling complex BAF in lymphomagenesis

Manoela Tiago dos Santos, Ph.D.

Thomas Jefferson University, Philadelphia, PA

PROJECT:  BET inhibition to optimize BRAFi/MEKi therapy for mutant BRAF

Yuanfan Yang, M.D.

Duke Univ Medical Center, Durham, NC

PROJECT: Anti-tumor efficacy of EGFR-targeting immunotoxin in combination with CCNU or PD-L1 blockade in glioma mouse models

Yuanyuan Li, Ph.D.

Icahn School of Medicine at Mt Sinai

PROJECT: IRAK1 Kinase drives cell survival in response to ionizing radiation and defines a target to overcome intrinsic tumor radioresistance

Siva Karthik Varanasi, Ph.D.

Salk Inst for Biological Studies

PROJECT: Evaluating the role of bile acids as a metabolic checkpoint of anti-tumor T cell Hepatocellular Carcinoma

Yuanyuan Xie, Ph.D.

Regents of the Univ of Colorado

PROJECT: Elucidating the functional and genomic impact of retrocopies on cancer

Joy Bianchi, M.D.

NYU Langone Health

PROJECT: Targeting copy number alterations to overcome immune evasion in melanoma

Shixin Ma, Ph.D.

The Salk Inst for Biological Studies

PROJECT: Metabolically harnessing anti-tumor CD8 T cells at epigenetic level

Haopeng Xiao, Ph.D.

Dana-Farber Cancer Institute

PROJECT: Proteomic approaches to investigate Redox control in cancer

Siang-Boon Koh, Ph.D.

Massachusetts General Hospital Cancer Center

PROJECT: Synergistic targeting of DNA damage response and EMT pathways to reverse RASAL2-driven chemoresistance